OBJECTIVES: This study sought to characterize factors influencing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) and to evaluate the ability of NT-proBNP to detect left ventricular (LV) dysfunction in a large community sample. BACKGROUND: Secretion of BNP increases in cardiac disease, making BNP an attractive biomarker. Amino-terminal proBNP, a fragment of the BNP prohormone, is a new biomarker. We evaluated factors influencing NT-proBNP in normal patients and compared the ability of NT-proBNP and BNP to detect LV dysfunction in a large community sample. METHODS: Amino-terminal pro-BNP was determined in plasma samples of a previously reported and clinically and echocardiographically characterized random sample (n = 1,869, age > or =45 years) of Olmsted County, Minnesota. RESULTS: In normal patients (n = 746), female gender and older age were the strongest independent predictors of higher NT-proBNP. Test characteristics for detecting an LV ejection fraction < or =40% or < or =50% were determined in the total sample with receiver operating characteristic curves. Amino-terminal pro-BNP had significantly higher areas under the curve for detecting an LV ejection fraction < or =40% or < or =50% than BNP in the total population and in several male and age subgroups, whereas areas were equivalent in female subgroups. Age- and gender-adjusted cutpoints improved test characteristics of NT-proBNP. Both assays detected patients with systolic and/or moderate to severe diastolic dysfunction to a similar degree, which was less robust than the detection of LV systolic dysfunction alone. CONCLUSIONS: Amino-terminal pro-BNP in normal patients is affected primarily by gender and age, which should be considered when interpreting values. Importantly, in the entire population sample NT-proBNP performed at least equivalently to BNP in detecting LV dysfunction and was superior in some subgroups in detecting LV systolic dysfunction.
OBJECTIVES: This study sought to characterize factors influencing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) and to evaluate the ability of NT-proBNP to detect left ventricular (LV) dysfunction in a large community sample. BACKGROUND: Secretion of BNP increases in cardiac disease, making BNP an attractive biomarker. Amino-terminal proBNP, a fragment of the BNP prohormone, is a new biomarker. We evaluated factors influencing NT-proBNP in normal patients and compared the ability of NT-proBNP and BNP to detect LV dysfunction in a large community sample. METHODS: Amino-terminal pro-BNP was determined in plasma samples of a previously reported and clinically and echocardiographically characterized random sample (n = 1,869, age > or =45 years) of Olmsted County, Minnesota. RESULTS: In normal patients (n = 746), female gender and older age were the strongest independent predictors of higher NT-proBNP. Test characteristics for detecting an LV ejection fraction < or =40% or < or =50% were determined in the total sample with receiver operating characteristic curves. Amino-terminal pro-BNP had significantly higher areas under the curve for detecting an LV ejection fraction < or =40% or < or =50% than BNP in the total population and in several male and age subgroups, whereas areas were equivalent in female subgroups. Age- and gender-adjusted cutpoints improved test characteristics of NT-proBNP. Both assays detected patients with systolic and/or moderate to severe diastolic dysfunction to a similar degree, which was less robust than the detection of LV systolic dysfunction alone. CONCLUSIONS: Amino-terminal pro-BNP in normal patients is affected primarily by gender and age, which should be considered when interpreting values. Importantly, in the entire population sample NT-proBNP performed at least equivalently to BNP in detecting LV dysfunction and was superior in some subgroups in detecting LV systolic dysfunction.
Authors: Allison M Pritchett; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer; Barry L Karon; Margaret M Redfield Journal: J Am Coll Cardiol Date: 2005-01-04 Impact factor: 24.094
Authors: Christopher R deFilippi; Robert H Christenson; Willem J Kop; John S Gottdiener; Min Zhan; Stephen L Seliger Journal: J Am Coll Cardiol Date: 2011-09-27 Impact factor: 24.094
Authors: Alain G Bertoni; Lynne E Wagenknecht; Dalane W Kitzman; Santica M Marcovina; Julia T Rushing; Mark A Espeland Journal: Obesity (Silver Spring) Date: 2011-09-29 Impact factor: 5.002
Authors: J Gustav Smith; Christopher Newton-Cheh; Peter Almgren; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Pyotr G Platonov; Bo Hedblad; Gunnar Engström; Thomas J Wang; Olle Melander Journal: J Am Coll Cardiol Date: 2010-11-16 Impact factor: 24.094
Authors: David L Garbers; Ted D Chrisman; Phi Wiegn; Takeshi Katafuchi; Joseph P Albanesi; Vincent Bielinski; Barbara Barylko; Margaret M Redfield; John C Burnett Journal: Trends Endocrinol Metab Date: 2006-06-30 Impact factor: 12.015
Authors: Paul M McKie; Richard J Rodeheffer; Alessandro Cataliotti; Fernando L Martin; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Margaret M Redfield; John C Burnett Journal: Hypertension Date: 2006-04-03 Impact factor: 10.190
Authors: F W Asselbergs; M P van den Berg; S J Bakker; J E Signorovitch; H L Hillege; W H van Gilst; D J van Veldhuisen Journal: Neth Heart J Date: 2008 Impact factor: 2.380